Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$83,896.00-0.86%ETH$2,687.00-0.12%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
MP

NASDAQ · MPLT

MapLight Therapeutics, Inc.

Healthcare · Biotechnology

$10.46

Down-$0.30 (-2.79%)

Updated Sep 27, 2026, 7:08 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.87M
P/E ratio
-8.1
Dividend yield
0.00%
52-week range
$9.10 – $40.43
Volume
317.5K
Avg. volume
385.16K

Price performance

MPLT price history

1M range · 19 trading sessions · Daily adjusted prices

MPLT closed at $10.46 after 19 trading sessions, down 19.35% for the selected period.

Last close
$10.46
Period change
-19.35%
Period low
$10.46
Period high
$13.95
Daily close
View OHLC price history
MPLT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 25, 2026$10.81$10.87$10.39$10.46317.5K
Sep 24, 2026$10.60$10.86$10.1601$10.76342.63K
Sep 23, 2026$10.89$10.93$10.13$10.77538.96K
Sep 22, 2026$11.02$11.2755$10.64$10.86411.39K
Sep 21, 2026$11.06$11.28$10.78$10.90542.94K
Sep 18, 2026$11.21$11.21$10.51$10.921.83M
Sep 17, 2026$11.57$11.7316$11.13$11.32545.85K
Sep 16, 2026$12.06$12.155$11.35$11.40613.87K
Sep 15, 2026$13.10$13.11$12.05$12.08402.35K
Sep 14, 2026$13.08$13.45$12.66$13.15327.56K
Sep 11, 2026$13.88$14.14$12.80$13.00340.17K
Sep 10, 2026$13.49$14.04$13.19$13.785490.31K
Sep 9, 2026$13.95$14.22$13.51$13.71500.69K
Sep 8, 2026$13.49$14.09$13.1928$13.95522.13K
Sep 4, 2026$13.03$14.14$13.00$13.77550.86K
Sep 3, 2026$13.20$13.45$12.96$13.14863.54K
Sep 2, 2026$13.33$13.9399$12.82$13.06937.69K
Sep 1, 2026$12.99$13.93$12.32$13.31580.67K
Aug 31, 2026$12.59$13.07$12.12$12.97440.58K

Latest MPLT news

The latest Smart Investors Daily articles mentioning MPLT.

Stock researchCompany · Overview

MPLT research

Overview

Company profile and research snapshot.

Company profile

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$31.00
Implied upside
—
Analysts
9
MPLT recent ratings
DateFirmRatingTarget
Aug 31, 2026NeedhamBuy—
Aug 10, 2026UBSNeutral—
Jul 28, 2026Canaccord GenuityBuy—
Jul 28, 2026Morgan StanleyEqual-Weight—
Jul 28, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 9, 2026

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomiz

Yahoo · Jan 5, 2026

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapi

globenewswire.com · Dec 4, 2025

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025 Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones. “2025 was a year of exceptional execution and acceleration for MapLight,” said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By